PATENT

DEC 1 5 2005 HE UNITED STATES PATENT AND TRADEMARK OFFICE

IN THE APPLICATION OF:

DAVID L. HALLAHAN ET. AL.

CASE NO.: CL2039USPCT

APPLICATION NO.: 10/532,013

CONFIRMATION NO.: 8994

GROUP ART UNIT: UNKNOWN

EXAMINER: UNKNOWN

FILED: NOVEMBER 12, 2003

FOR: CIS-PRENYLTRANSFERASES FROM THE RUBBER-PRODUCING PLANTS RUSSIAN DANDELION (TARAXACUM KOK-SAGHYZ) AND SUNFLOWER

(HELIANTHUS ANNUS)

RESPONSE TO NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 Attention: Mail Stop Sequence

Sir:

In response to the Notice to Comply With Requirements for Patent Applications Containing Nucleotide And/Or Amino Acid Sequence Disclosures mailed October 26, 2005 (a copy of which is attached), enclosed is a computer readable form, a paper copy of the Sequence Listing, and a statement that the content of the sequence listing recorded on the computer readable form is identical to the paper copy for the above-referenced application. Should any fee be required in connection with the filing of this Information Disclosure Statement, please charge such fee to Deposit Account No. 04-1928 (E. I. du Pont de Nemours and Company).

Respectfully submitted,

S. NEIL FELTHAM

ATTORNEY FOR APPLICANTS

Registration No.: 36,506 Telephone: (302) 992-6460 Facsimile: (302) 992-5374

12/05

Rec'd PCT/PTO

15/DEC 2005



PTO/SB/92 (09-04)

Approved for use through 07/31/2006. OMB 0561-0031

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Date

Diane


Dia

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

10/532,013

CL2039USPCT

RESPONSE TO NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES COMPUTER READABLE FORM OF SEQUENCE LISTING PAPER COPY OF SEQUENCE LISTING - 48 PAGES STATEMENT IN ACCORDANCE WITH 37 CFR 1.821





UNITED STATES DEPARTMENT OF COMMERC United States Patent and Trademark Office
Address COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Viginia 22313-1450
www.uspto.gov

U.S. APPLICATION NUM

FIRST NAMED APPLICANT

ATTY. DOCKET NO.

10/532,013

David L. Hallahan

CL2039USPCT

INTERNATIONAL APPLICATION NO.

PCT/US03/36164

I.A. FILING DATE

PRIORITY DATE

11/12/2003

11/13/2002

Sabine Epelbaum

E I Du Pont De Nemours and Company Legal Patent Records Center

4417 Lancaster Pike Wilmington, DE 19805

CONFIRMATION NO. 8994

371 FORMALITIES LETTER

OC000000017326118

Date Mailed: 10/26/2005

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

 A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:


- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice **MUST** be returned with the response.

JOHN L ANDERSON





PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/532.013	PCT/US03/36164	CL2039USPCT

FORM PCT/DO/EO/922 (371 Formalities Notice)